Terms: = Brain cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
727 results:
1. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
[TBL] [Abstract] [Full Text] [Related]
2. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung cancer Treated with PD-1/pd-l1 Inhibitors: A Single Institutional Cohort Study.
Yuan Q; Xu C; Wang W; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
[TBL] [Abstract] [Full Text] [Related]
3. pd-l1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence.
Huang L; Chen S; Liu H; Meng L; Liu C; Wu X; Wang Y; Luo S; Tu H; Wang C; Zhang M; Gong X
Cancer Med; 2024 Apr; 13(7):e7125. PubMed ID: 38613182
[TBL] [Abstract] [Full Text] [Related]
4. [Expression of immune checkpoints pd-l1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
[TBL] [Abstract] [Full Text] [Related]
5. Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer.
Divan HA; Bittoni MA; Krishna A; Carbone DP
BMC Cancer; 2024 Apr; 24(1):424. PubMed ID: 38580900
[TBL] [Abstract] [Full Text] [Related]
6. Relevance of Thymic Stromal Lymphopoietin on the Pathogenesis of Glioblastoma: Role of the Neutrophil.
Infante Cruz A; Coronel JV; Saibene Vélez P; Remes Lenicov F; Iturrizaga J; Abelleyro M; Rosato M; Shiromizu CM; Candolfi M; Vermeulen M; Jancic C; Yasuda E; Berner S; Villaverde MS; Salamone GV
Cell Mol Neurobiol; 2024 Apr; 44(1):31. PubMed ID: 38557942
[TBL] [Abstract] [Full Text] [Related]
7. Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer.
Zhou Y; Li H; Zhang Y; Zhao E; Huang C; Pan X; Shu F; Liu Z; Tang N; Li F; Liao W
Cancer Lett; 2024 May; 589():216836. PubMed ID: 38556105
[TBL] [Abstract] [Full Text] [Related]
8. Potential value of expression of receptor accessory protein 4 for evaluating the prognosis of lower-grade glioma patients.
Luo S; Liu Z; Chang H; Cheng X; Qian R; Gao Y; Hou C
Aging (Albany NY); 2024 Mar; 16(7):6188-6211. PubMed ID: 38552216
[TBL] [Abstract] [Full Text] [Related]
9. Associations of PD-1 and pd-l1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
10. Outcomes of Patients with Non-Small Cell Lung cancer and brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.
Nannini S; Guisier F; Curcio H; Ricordel C; Demontrond P; Abdallahoui S; Baloglu S; Greillier L; Chouaid C; Schott R
Curr Oncol; 2024 Mar; 31(3):1656-1666. PubMed ID: 38534959
[TBL] [Abstract] [Full Text] [Related]
11. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
12. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Leonetti A; Perrone F; Puntoni M; Maglietta G; Bordi P; Bria E; Vita E; Gelsomino F; De Giglio A; Gelibter A; Siringo M; Mazzoni F; Caliman E; Genova C; Bertolini F; Guaitoli G; Passiglia F; Delcuratolo MD; Montrone M; Cerea G; Pasello G; Roca E; Belluomini L; Cecere FL; Guida A; Manzo A; Adamo V; Rastelli F; Bulotta A; Citarella F; Toschi L; Zoratto F; Cortinovis DL; Berardi R; Follador A; Carta A; Camerini A; Salerno F; Silva RR; Baldini E; Cortellini A; Brighenti M; Santoni M; Malorgio F; Caminiti C; Tiseo M
Eur J Cancer; 2024 May; 202():114006. PubMed ID: 38489861
[TBL] [Abstract] [Full Text] [Related]
13. Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
Leal TA; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Liu SV
JCO Glob Oncol; 2024 Mar; 10():e2300483. PubMed ID: 38484195
[TBL] [Abstract] [Full Text] [Related]
14. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N
Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774
[TBL] [Abstract] [Full Text] [Related]
15. Predictive role of intracranial pd-l1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection.
Wasilewski D; Onken J; Höricke P; Bukatz J; Murad S; Früh A; Shaked Z; Misch M; Kühl A; Klein O; Ehret F; Kaul D; Radbruch H; Capper D; Vajkoczy P; Horst D; Frost N; Bischoff P
J Neurooncol; 2024 Mar; 167(1):155-167. PubMed ID: 38358406
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy of PD-1/pd-l1 immunotherapy on brain metastatic non-small-cell lung cancer and treatment-related adverse events: A systematic review.
Phillips W; Thornton Z; Andrews L; Daly R; Higgins J; Davies P; Kurian K
Crit Rev Oncol Hematol; 2024 Apr; 196():104288. PubMed ID: 38331301
[TBL] [Abstract] [Full Text] [Related]
17. Cediranib enhances the transcription of MHC-I by upregulating IRF-1.
Zhang J; Guo H; Wang L; Zheng M; Kong S; Wu H; Zhao L; Zhao Q; Yang X; He Q; Chen X; Ding L; Yang B
Biochem Pharmacol; 2024 Mar; 221():116036. PubMed ID: 38301967
[TBL] [Abstract] [Full Text] [Related]
18. The treatment of advanced melanoma: Current approaches and new challenges.
Boutros A; Croce E; Ferrari M; Gili R; Massaro G; Marconcini R; Arecco L; Tanda ET; Spagnolo F
Crit Rev Oncol Hematol; 2024 Apr; 196():104276. PubMed ID: 38295889
[TBL] [Abstract] [Full Text] [Related]
19. Integrative analysis of the cuproptosis-related gene ATP7B in the prognosis and immune infiltration of IDH1 wild-type glioma.
Zhang K; Qu C; Zhou P; Yang Z; Wu X
Gene; 2024 May; 905():148220. PubMed ID: 38286269
[TBL] [Abstract] [Full Text] [Related]
20. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
[Next]